SEC Form 3 · accession 0001808296-26-000006
Latigo Biotherapeutics, Inc. · LTGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nima Farzan
Officer — President and CEO · Director
Period of report
Aug 6, 2026
Accepted (ET)
Aug 6, 2026 · 8:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0002056611
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 114,453 | I | By Farzan 2026 Descendants' Trust f/b/o ZAF |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $2.19 | holding | — | — | — | — | Jul 30, 2034 | Common Stock | 1,703,288 | — | D |
| Employee Stock Option (right to buy)F3 | $5.53 | holding | — | — | — | — | Feb 4, 2035 | Common Stock | 676,468 | — | D |
| Employee Stock Option (right to buy)F3 | $5.53 | holding | — | — | — | — | Apr 7, 2035 | Common Stock | 136,070 | — | D |
| Employee Stock Option (right to buy)F3 | $5.53 | holding | — | — | — | — | Apr 7, 2035 | Common Stock | 272,140 | — | D |
Explanation of responses
- F1The Reporting Person is trustee of Farzan 2026 Descendants' Trust f/b/o ZAF
- F2One-fourth of the total shares subject to this option shall vest one year after July 15, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F3One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.